Funding structures that ordinary accounting does not anticipate
A conventional business earns revenue from customers. A substantial share of the Masdar City population does something more complicated: research funded by grants, projects financed under specific arrangements, technology developed under partnership agreements, and revenue that may arrive years after the expenditure that generated it.
That produces accounting questions a standard setup does not address. When is grant income recognised — on award, on receipt, or as the related expenditure occurs? Are development costs on a clean technology asset capitalised, and against what evidence of future benefit? How is a project asset with a twenty-five year life depreciated when the revenue profile is nothing like straight line?
Getting these wrong does not usually create a tax problem in the first year. It creates a set of accounts that misrepresents the business to everyone who reads them, including the people running it.
Who this is for
Masdar City companies in renewable energy and clean technology, environmental services, research and development organisations, sustainability consultancies, and the technology and professional services firms based in the zone.
Particularly organisations receiving grant or project funding, businesses with long-cycle asset investments, and companies developing technology where the capitalisation question is live.
What the work involves
How we run it:
- Set the grant recognition policy — whether income is recognised as the related costs are incurred, on satisfaction of conditions, or on receipt, and document why.
- Establish development cost treatment, applying the capitalisation criteria properly rather than by preference.
- Account for long-life project assets, including depreciation profile and impairment triggers.
- Handle partnership and consortium arrangements, including whether an arrangement is a joint operation or a joint venture, which changes presentation entirely.
- Assess the ESR position where intellectual property or headquarters activity is involved.
- Manage the reverse charge on overseas research, software and consultancy costs.
- Prepare financial statements with the judgements documented.
- Handle corporate tax and VAT, including the treatment of grant income for tax purposes.
Grants and project funding
Grant accounting is governed by conditions rather than by cash, and the distinction determines the timing of everything:
- Conditional grants — recognised as income when the conditions are met, not when the money arrives; until then the receipt is a liability
- Grants relating to expenditure — recognised across the periods in which the related costs are incurred, so income and cost are matched
- Grants relating to assets — either deducted from the asset’s carrying amount or recognised as deferred income across the asset’s life
- Repayable elements — where a grant becomes repayable on certain outcomes, that contingency must be assessed and disclosed
- Tax treatment — grant income does not automatically follow the accounting treatment for corporate tax purposes, and the two need reconciling
- Restricted funds — where use is restricted, tracking has to be at fund level, not just in aggregate
The most common error is recognising a grant on receipt. It flatters the period the cash arrives, creates a mismatch against the costs it was meant to fund, and produces a profit figure that describes the funding cycle rather than the business.
Long-life assets and impairment
A renewable energy or infrastructure asset may have a life of twenty to thirty years, with revenue that varies substantially across it. Straight-line depreciation is the default and is frequently not the best reflection of how the asset’s benefits are consumed.
Where output declines predictably — as with generation assets — a units-of-production basis may better match the charge to the benefit. That is a policy decision requiring evidence, not a preference, and it should be documented when it is made.
Impairment is the harder question. Clean technology is a sector where economics change quickly: input costs fall, technology is superseded, and offtake arrangements are renegotiated. Each of those can be an impairment indicator, and the assessment has to be made when the indicator arises rather than at a convenient moment. An asset carried at a value the current economics do not support is the most consequential misstatement available to a business in this sector.
What goes wrong
These are the failures we are brought in to correct, in rough order of frequency:
- Recognising grant income on receipt rather than as conditions are met or costs incurred.
- No liability recognised for grant money received against conditions not yet satisfied.
- Development costs capitalised without meeting the criteria, or expensed without considering whether they should be.
- Straight-line depreciation applied by default to assets whose benefits are not consumed that way.
- Impairment assessed only at year end, when the indicator arose in month four.
- Consortium arrangements presented without determining whether they are joint operations or joint ventures.
- Grant income assumed to follow the accounting treatment for corporate tax purposes.
Deadlines that apply
Grant recognition and development cost policies should be set when the funding arrangement is entered into, not at the year end — because the conditions attached to the funding determine the accounting, and reading them afterwards means restating.
Impairment indicators should be assessed as they arise. Corporate tax follows at 30 September 2026 for a December year end, and the ESR position should be established early in the period where IP or headquarters activity is involved.
What lands on your desk
- Grant recognition policy documented against the actual funding conditions
- Development cost capitalisation criteria applied consistently
- Depreciation policy matched to how asset benefits are consumed
- Impairment assessment framework with defined indicators
- ESR assessment where IP or headquarters activity applies
- Financial statements with judgements documented
- Corporate tax return, including reconciliation of grant income treatment
What we need from you
The list is short and you will have most of it already:
- Masdar City licence and activity details
- Grant and funding agreements, in full, including conditions
- Project agreements and consortium arrangements
- Development cost records by project
- Fixed asset register with expected lives and output profiles
- Details of intellectual property held or developed
- Overseas supplier and research costs
- Prior year financial statements
What it costs
Bookkeeping is priced on transaction volume, which for a research or project business is usually low relative to its balance sheet. The policy work — grants, development costs, asset lives — is a one-off fixed fee and is where the value is, because those judgements then govern every subsequent period.
ESR and transfer pricing work, where IP arrangements exist, is quoted separately.
Related
Frequently Asked Questions
When is grant income recognised?
When the conditions attached to it are met, or across the periods in which the related expenditure is incurred — not on receipt. Money received against conditions not yet satisfied is a liability. Recognising on receipt produces a profit figure that describes the funding cycle rather than the business.
How are grants relating to assets treated?
Either deducted from the asset’s carrying amount, or recognised as deferred income released across the asset’s useful life. Both are acceptable; what matters is choosing one, documenting why, and applying it consistently.
Does grant income follow the accounting treatment for corporate tax?
Not automatically. The tax treatment has to be considered separately and reconciled to the accounting position, and an unexplained difference between your own accounts and your own return is exactly the kind of thing that generates a question.
Should we depreciate a generation asset on a straight line?
Not necessarily. Where output and therefore benefit decline predictably, a units-of-production basis may match the charge to the benefit more accurately. It is a policy decision requiring evidence and documentation rather than a preference.
When should we test for impairment?
When an indicator arises, not at a convenient moment. In clean technology, indicators include falling input costs, superseded technology and renegotiated offtake arrangements — all of which can occur mid-year. An asset carried above what current economics support is the most consequential misstatement available in this sector.
Can we capitalise our R&D?
Development costs meeting the criteria — technical feasibility, intention and ability to complete, probable future economic benefits — may be capitalised. Research is expensed. The distinction requires evidence rather than intent, and it is tested by auditors carefully in this sector.
We are in a consortium on a project. How is that presented?
It depends whether the arrangement is a joint operation or a joint venture, which turns on the rights and obligations of the parties rather than on the legal form. The two are presented completely differently, so the determination has to be made and documented at the outset.
It is the most common error in this population, and it makes the accounts describe the funding cycle rather than the business. Send us the funding agreements.
Check my compliance status 058 101 9570
Last reviewed 27 July 2026. Rates, thresholds and deadlines change — the e-invoicing provider deadline has already moved once. Confirm current requirements with the Federal Tax Authority before acting, or ask us to check your position.